Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)

Monika Sparber-Sauer,Sabine Stegmaier,Christian Vokuhl,Guido Seitz,Thekla von Kalle,Monika Scheer,Marc Münter,Stefan S. Bielack,Jadwiga Weclawek‐Tompol,Ruth Ladenstein,Felix Niggli,Gustaf Ljungman,Joerg Fuchs,Simone Hettmer,Ewa Koscielniak,Thomas Klingebiel

Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)

2019

Monika Sparber-Sauer
Sabine Stegmaier
Christian Vokuhl
Guido Seitz
Thekla von Kalle
Monika Scheer
Marc Münter
Stefan S. Bielack
Jadwiga Weclawek‐Tompol
Ruth Ladenstein
Felix Niggli
Gustaf Ljungman
Joerg Fuchs
Simone Hettmer
Ewa Koscielniak
Thomas Klingebiel

Background Rhabdomyosarcoma (RMS) diagnosed during the first year of life is reported to have poor outcome. Little is known about treatment and outcome data of relapsed disease (RD).MethodsCharacte ...

Keywords:

Localized disease
Intensive care medicine
Pediatrics
RELAPSED DISEASE
Rhabdomyosarcoma
Medicine
outcome data
Hematology
Pathology
Internal medicine
Chemotherapy
Radiation therapy
first year of life

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations